Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05827081
Title	Phase IIIb Study of Ribociclib + ET in Early Breast Cancer (Adjuvant WIDER)
Acronym	Adjuvant WIDER
Recruitment	Suspended
Gender	both
Phase	Phase III
Variant Requirements	No
Sponsors	Novartis Pharmaceuticals
Indications	Her2-receptor negative breast cancer
Therapies	Exemestane + Leuprolide + Ribociclib Letrozole + Leuprolide + Ribociclib Goserelin + Letrozole + Ribociclib Anastrozole + Ribociclib Anastrozole + Goserelin + Ribociclib Exemestane + Goserelin + Ribociclib Exemestane + Ribociclib Anastrozole + Leuprolide + Ribociclib Letrozole + Ribociclib
Age Groups:	adult \| senior
Covered Countries	AUS